335 results match your criteria Skin Therapy Letter[Journal]


Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis

Skin Therapy Lett 2019 Mar;24(2):4-6

Division of Dermatology, University of Alberta, Edmonton, AB, Canada

Atopic dermatitis is a common cutaneous disease with significant morbidity affecting children and adults. The mainstay of atopic dermatitis therapy has typically included emollients, topical corticosteroids, and topical calcineurin inhibitors. Among the newer advances recently introduced is crisaborole (Eucrisa™), a phosphodiesterase type-4 inhibitor (PDE-4) for the treatment of mild moderate atopic dermatitis. Read More

View Article

Download full-text PDF

Source

Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis

Skin Therapy Lett 2019 Mar;24(2):1-3

Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA

Hyperhidrosis is a condition characterized by excessive sweat production beyond which is physiologically necessary for thermal regulation. Affecting over 4.8% of the United States population, studies have shown that severe primary hyperhidrosis interferes with daily activities and can be considered intolerable, negatively impacting a patient’s quality of life. Read More

View Article

Download full-text PDF

Source
March 2019
1 Read

Update on Immunotherapeutics in the Management of Metastatic Melanoma

Skin Therapy Lett 2019 Jan;24(1):8-11

Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada

Today, a number of treatment options are now available for metastatic melanoma. Within the last decade, the development of novel immunotherapies for cancer has significantly altered the course of the disease in patients with melanoma. With more patients receiving these potentially life-saving treatments, not only have we learned more about the interplay between the immune system and melanoma, but more importantly, which treatment options are most appropriate given the clinical picture. Read More

View Article

Download full-text PDF

Source
January 2019
3 Reads

The Treatment of Primary Focal Hyperhidrosis

Skin Therapy Lett 2019 01;24(1):1-7

Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA

Primary focal hyperhidrosis is a relatively common disease that has a significant impact on afflicted patient’s quality of life. The pathogenesis of the disease is thought to stem from increased cholinergic activity on eccrine sweat glands. Topical aluminum chloride based antiperspirants are good first-line agents for all affected body sites. Read More

View Article

Download full-text PDF

Source
January 2019
12 Reads

Afamelanotide in the Treatment of Dermatologic Disease

Skin Therapy Lett 2018 11;23(6):6-10

Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments. Its efficacy has been demonstrated in several dermatologic conditions, including erythropoietic protoporphyria (EPP), solar urticaria, polymorphic light eruption (PMLE), vitiligo, acne, and Hailey-Hailey disease. Its relatively low risk side effect profile makes it an attractive treatment option and also paves the way for innovative use in other disorders. Read More

View Article

Download full-text PDF

Source
November 2018
7 Reads

The Therapeutic Potential of Cannabinoids in Dermatology

Skin Therapy Lett 2018 11;23(6):1-5

Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA

Cannabinoids have demonstrated utility in the management of cancer, obesity, and neurologic disease. More recently, their immunosuppressive and anti-inflammatory properties have been identified for the treatment of several dermatologic conditions. This review thus assesses the therapeutic potential of phytocannabinoids, endoocannabinoids, and chemically synthetic cannabinoids in the management of cutaneous disease. Read More

View Article

Download full-text PDF

Source
November 2018
5 Reads

Chronic Pruritus: A Review of Neurophysiology and Associated Immune Neuromodulatory Treatments.

Authors:
J M Patel H Dao

Skin Therapy Lett 2018 09;23(5):5-9

Department of Dermatology, Baylor College of Medicine, Houston, TX, USA.

Chronic pruritus remains a difficult condition to treat with many non-specific therapeutic options. Recent scientific discoveries have elucidated the physiology associated with pruritus. Combined with clinical and experimental trials with immune-modulatory agents, chronic pruritus now has novel treatment options with known mechanisms of action. Read More

View Article

Download full-text PDF

Source
September 2018
1 Read

Non-Invasive Gene Expression Testing to Rule Out Melanoma.

Skin Therapy Lett 2018 09;23(5):1-4

Department of Dermatology, New York University Medical Center, New York, NY, USA.

The Pigmented Lesion Assay (PLA) is a gene expression test that helps rule out melanoma and has the potential to reduce the need for surgical biopsies of atypical pigmented skin lesions. Utilizing a new technological platform for the non-invasive profiling of skin, the assay analyzes samples collected from adhesive patches for expression of two key genes (PRAME and LINC00518) known to be overexpressed in melanoma. The test result is binary (positive/negative) based on the detection of one or both genes. Read More

View Article

Download full-text PDF

Source
September 2018
1 Read

The Evolution of Topical Formulations in Psoriasis.

Authors:
B Kuehl N H Shear

Skin Therapy Lett 2018 07;23(4):5-9

Sunnybrook Health Sciences Centre, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada.

Most people with mild-to-moderate psoriasis manage their disease with topical therapies. However, adherence to topical treatment remains a challenge, as the daily application creates a significant treatment burden. New topical therapeutic options need to offer higher efficacy and better patient acceptability, including easier application, to reduce treatment burden and enhance patient adherence. Read More

View Article

Download full-text PDF

Source
July 2018
1 Read

Alitretinoin: An Update of Real-World Evidence in The Management of Chronic Hand Dermatitis.

Authors:
M J Gooderham

Skin Therapy Lett 2018 07;23(4):1-4

Skin Centre for Dermatology, Peterborough, ON, Canada; Probity Medical Research, Waterloo, ON, Canada; Queen's University, Kingston, ON, Canada.

Chronic hand dermatitis is a debilitating inflammatory dermatosis that has a significant impact on the quality of life of those affected. Alitretinoin is an oral retinoid which has proven efficacy and safety in the treatment of chronic hand dermatitis through randomized controlled trials. Real-world evidence, information gathered in the clinic or community setting, as opposed to a research environment, can complement knowledge gained from clinical trials. Read More

View Article

Download full-text PDF

Source
July 2018
5 Reads

Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology

Skin Therapy Lett 2018 05;23(3):5-9

Division of Dermatology, University of Calgary, Calgary, AB, Canada.

The class of medications known as Janus kinase inhibitors block cytokine-mediated signaling via the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, which plays an important role in immunoregulation and normal cell growth. This class includes the drugs tofacitinib, approved for the treatment of rheumatoid arthritis, and ruxolitinib, approved for the treatment of myelofibrosis and polycythemia rubra vera. The most common adverse events (AEs) reported in patients taking tofacitinib are infections, whereas the most common AEs in patients taking ruxolitinib are anemia and thrombocytopenia. Read More

View Article

Download full-text PDF

Source
May 2018
5 Reads

Chronic Urticaria: Following Practice Guidelines.

Skin Therapy Lett 2018 05;23(3):1-4

Department of Medicine, University of Toronto, Toronto, ON, Canada; Gordon Sussman Clinical Research, Toronto, ON, Canada; Division of Allergy and Clinical Immunology, St. Michael's Hospital, Toronto, ON, Canada.

Histamine is a key inflammatory player in the pathogenesis of urticaria, a mast-cell-driven disease characterized clinically by the development of wheals, angioedema, or both. Changes to the management of chronic spontaneous urticaria have recently been adopted due to increasing literature surrounding the efficacy and safety of up-dosing modern second-generation H-antihistamines and the use of omalizamub, a biologic agent, as a third-line treatment. Given the prevalence of chronic urticaria and its impact on quality of life, this editorial aims to provide a summary of the proposed updated guidelines for the management of chronic urticaria as agreed upon at the 5th Consensus Conference on the Update and Revision of the EAACI/GALEN/EDF/WAO Guideline for Urticaria in Berlin in December 2016. Read More

View Article

Download full-text PDF

Source
May 2018
10 Reads

A Review of Fabry Disease.

Authors:
B Chan D N Adam

Skin Therapy Lett 2018 03;23(2):4-6

Baywood Dermatology, Ajax, ON, Canada; CCA Medical Research, Ajax, ON, Canada; St. Michael's Hospital, Toronto, ON, Canada; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Probity Medical Research, Waterloo, ON, Canada.

Fabry disease (FD) is an X-linked lysosomal storage disease. A lack of alpha-galactosidase activity results in the accumulation of globotriaosylceramide in cells of various systems, leading to multi-systemic effects. The cutaneous hallmark of FD is a specific distribution of angiokeratoma. Read More

View Article

Download full-text PDF

Source
March 2018
3 Reads

Brodalumab: A Review of Safety.

Skin Therapy Lett 2018 03;23(2):1-3

Probity Medical Research, Waterloo, ON Canada; K Papp Clinical Research, Waterloo, ON Canada.

Interleukin (IL)-17 is important in the pathophysiology of psoriasis and has proven to be an effective therapeutic target. Brodalumab, the third commercially available IL-17 antagonist, was approved by the US FDA in February 2017 for the treatment of moderate-tosevere plaque psoriasis. As brodalumab enters the marketplace, it is imperative to investigate its safety profile. Read More

View Article

Download full-text PDF

Source
March 2018
3 Reads

New Treatments for Hereditary Angioedema.

Skin Therapy Lett 2018 01;23(1):6-8

Virginia Tech Carilion School of Medicine, Roanoke, VA, USA; Carilion Clinic Dermatology & Mohs Surgery, Roanoke, VA, USA.

Hereditary angioedema is characterized by severe, episodic edema of the subcutaneous and mucosal tissue. The disease carries significant morbidity and mortality due to involvement of the gastrointestinal tract and upper airway. Recent advances in the treatment of hereditary angioedema include new techniques used to isolate and purify human-derived C1 inhibitor, the production of a recombinant form of C1 inhibitor, and the development of drugs that target the kallikrein-kinin pathway. Read More

View Article

Download full-text PDF

Source
January 2018
24 Reads

Skin and Diet: An Update on the Role of Dietary Change as a Treatment Strategy for Skin Disease.

Skin Therapy Lett 2018 01;23(1):1-5

Georgetown University School of Medicine, Washington, DC, USA.

An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. Certain nutrients, foods, or dietary patterns may act as disease "triggers", while others may prove beneficial. Read More

View Article

Download full-text PDF

Source
January 2018
10 Reads

Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea.

Skin Therapy Lett 2017 11;22(6):5-7

Department of Dermatology, Weill Medical College of Cornell University, New York, NY, USA.

Approximately 16 million Americans have rosacea, an inflammatory cutaneous disorder with central facial erythema, papules, pustules, telangiectasia, flushing, and swelling being among the more commonly recognized features. Overexpression of cathelicidin peptide LL-37 has been implicated in the pathophysiology of rosacea. Azelaic acid has been found to inhibit the pathologic expression of cathelicidin, as well as the hyperactive protease activity that cleaves cathelicidin into LL-37. Read More

View Article

Download full-text PDF

Source
November 2017
5 Reads

Dupilumab for Moderate-to-Severe Atopic Dermatitis.

Skin Therapy Lett 2017 11;22(6):1-4

School of Medicine, Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA

Atopic dermatitis (AD) is the most common chronic inflammatory disease affecting 2-10% of adults and up to 15-30% of children. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option. Read More

View Article

Download full-text PDF

Source
November 2017
10 Reads

Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management.

Authors:
S Monjazeb J Wilson

Skin Therapy Lett 2017 Sep;22(5):5-7

School of Medicine, Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA.

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Read More

View Article

Download full-text PDF

Source
September 2017
4 Reads

Vitamin B Derivative (Nicotinamide)Appears to Reduce Skin Cancer Risk.

Authors:
S Nazarali P Kuzel

Skin Therapy Lett 2017 Sep;22(5):1-4

University of Alberta, Faculty of Medicine and Dentistry, Edmonton, AB, Canada.

Nicotinamide, an amide form of vitamin B3, has shown the potential to treat a variety of dermatological conditions, including acne, rosacea, and atopic dermatitis. Recent studies have demonstrated the role of nicotinamide, in both topical and oral forms, as a chemopreventive agent against skin cancer. Its anti-carcinogenic role may be due to its ability to enhance DNA repair and prevent ultraviolet (UV)-induced immunosuppression, which is known to contribute to the progression of pre-malignant lesions. Read More

View Article

Download full-text PDF

Source
September 2017
25 Reads

Hepatitis B and C Viruses and Biologics.

Authors:
P Grewal R Sanghera

Skin Therapy Lett 2017 Jul;22(4):7-9

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, AB, Canada.

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are common, worldwide viral illnesses that potentially impact the clinician's ability to manage patients with immunosuppressive medications such as biological therapy. In light of recent literature reviews, patients with HBV and HCV should be referred to a hepatologist or infectious disease expert prior to initiation of biological therapy. Read More

View Article

Download full-text PDF

Source
July 2017
4 Reads

Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.

Skin Therapy Lett 2017 07;22(4):1-6

Department of Dermatology, Psoriasis and Skin Treatment Center, University of California - San Francisco, San Francisco, CA, USA.

While there are several commercially available treatment options for psoriasis and psoriatic arthritis, there remains a large number of individuals who are refractory to current modalities. In the recent past, there has been increasing evidence that interleukin (IL)-17 plays a vital role in the pathophysiology of psoriasis. Preclinical, phase II, and phase III studies of secukinumab (Cosentyx®) targeting IL-17 and its receptor have thus far proved to be promising. Read More

View Article

Download full-text PDF

Source
July 2017
37 Reads

The Role of Skin Care in Optimizing Treatment of Acne and Rosacea.

Authors:
C Zip

Skin Therapy Lett 2017 May;22(3):5-7

Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada.

A triad approach to the treatment of acne and rosacea has been recommended. This integrated management approach includes patient education, selection of therapeutic agents, and initiation of an appropriate skin care regime. Proper skin care in patients undergoing treatment of both acne and rosacea includes use of products formulated for sensitive skin that cleanse, moisturize and photoprotect the skin. Read More

View Article

Download full-text PDF

Source
May 2017
7 Reads

A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.

Skin Therapy Lett 2017 Mar;22(2):8-10

Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA.

Psoriasis is a chronic inflammatory skin disorder that affects 2% of the population. Evidence suggests that interleukin (IL)-23 plays a pivotal role in the pathogenesis of psoriasis. Guselkumab is a subcutaneously administered, humanized anti-IL23 monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis. Read More

View Article

Download full-text PDF

Source
March 2017
7 Reads

Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.

Skin Therapy Lett 2017 Mar;22(2):1-7

University of Toronto Department of Medicine, Toronto, ON, Canada; Lynde Institute for Dermatology, Markham, ON, Canada.

Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis. Tofacitinib inhibits Janus kinases (JAKs), which are essential for the signaling of multiple inflammatory pathways and have been implicated in the pathogenesis of RA and psoriasis. The efficacy and safety of tofacitinib in the treatment of RA and psoriasis have been demonstrated in Phase III trials. Read More

View Article

Download full-text PDF

Source
March 2017
8 Reads

A Dermatologist's Guide to Infection Screening Prior to Initiating Immunosuppressive Therapy.

Authors:
M G Ponzo C H Hong

Skin Therapy Lett 2017 Jan;22(1):8-11

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada; Division of Dermatology, St. Paul's Hospital, Vancouver, BC, Canada.

Dermatologists have within their armamentarium numerous immunosuppressant agents, both traditional and new, that are useful in the treatment of chronic cutaneous disorders such as autoimmune bullous diseases and psoriasis. It is imperative that users of these agents are aware of potential sequelae from therapy, particularly infections. In this review, we summarize the most common immunosuppressant medications currently used in dermatology, and provide recommendations for infection screening prior to initiating treatment. Read More

View Article

Download full-text PDF

Source
January 2017
5 Reads

A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.

Skin Therapy Lett 2017 Jan;22(1):1-6

Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutralizes IL-17 receptor type A. Read More

View Article

Download full-text PDF

Source
January 2017
5 Reads

Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis.

Skin Therapy Lett 2016 Nov;21(6):7-11

Mediprobe Research Inc., London, ON, Canada.

Efinaconazole 10% nail solution is a novel topical antifungal drug for the treatment of onychomycosis. Two Phase III trials were completed using efinaconazole 10% nail solution, where 17.8% and 15. Read More

View Article

Download full-text PDF

Source
November 2016
12 Reads

A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.

Skin Therapy Lett 2016 Nov;21(6):1-6

Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA.

Psoriasis is a multifactorial chronic skin disease that can have significant detrimental effects on patients' physical, mental, antibodypsychosocial wellbeing. Patients often suffer from a decreased quality of life along with numerous comorbidities. Recent advances in our understanding of the innate and adaptive immune systems have led to the identification of interleukin (IL)-17 as a key pro-inflammatory mediator in psoriasis. Read More

View Article

Download full-text PDF

Source
November 2016
9 Reads

Rituximab: Uses in Dermatology.

Skin Therapy Lett 2016 Sep;21(5):5-7

Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA.

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Chronic graft-versus-host disease and pemphigus vulgaris are two of the most promising indications for off-label use of rituximab. It is a generally safe alternative that should be considered when traditional therapy with corticosteroids or immunosuppressants has failed or caused significant intolerance. Read More

View Article

Download full-text PDF

Source
September 2016
9 Reads

Sodium Deoxycholate for Submental Contouring.

Skin Therapy Lett 2016 Sep;21(5):1-4

Department of Ophthalmology and Visual Science, University of British Columbia, Vancouver, BC, Canada.

The chin and jaw line are integral parts of an individual's aesthetic profile, and the presence of submental fat detracts from this and can lead to displeasure with one's facial appearance. While liposuction and cosmetic surgery are regarded as the gold standard in treating submental fat, surgical intervention is not appealing to all patients and has potential surgical complications including longer recovery, and contour irregularities. Despite ample advances in aesthetic medicine to enhance the appearance of the face, very little is available in non-invasive options to reduce submental fat that has been supported by robust evidence. Read More

View Article

Download full-text PDF

Source
September 2016
7 Reads

Frontal Fibrosing Alopecia.

Authors:
S Holmes

Skin Therapy Lett 2016 Jul;21(4):5-7

Alan Lyell Centre for Dermatology, Glasgow, UK.

Frontal fibrosing alopecia, described just over 20 years ago, has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. Considered a clinical variant of lichen planopilaris (LPP), it has distinctive features and associations which distinguish it from LPP. Although largely affecting postmenopausal women, a small but increasing number of men and premenopausal women are affected. Read More

View Article

Download full-text PDF

Source
July 2016
10 Reads

Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.

Skin Therapy Lett 2016 Jul;21(4):1-4

Mediprobe Research Inc., London, ON, Canada.

Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Results of two Phase III trials of adalimumab demonstrate significantly higher efficacies compared to placebo. Primary efficacy outcome of 50% reduction in abscess and inflammatory nodule count was seen in 41. Read More

View Article

Download full-text PDF

Source
July 2016
16 Reads

Off-Label Uses of Topical Calcineurin Inhibitors.

Authors:
E Wong A Kurian

Skin Therapy Lett 2016 Jan;21(1):8-10

Division of Dermatology & Cutaneous Sciences, Department of Medicine, University of Alberta, Edmonton, AB, Canada.

Topical calcineurin inhibitors (TCIs) have been proposed as an alternative, long-term treatment option to topical corticosteroids, without the side effects commonly associated with steroid use. Currently, TCIs are only approved for treatment of atopic dermatitis in patients 2 years of age or older. This article reviews the off-label uses of TCIs and their efficacy in the treatment of cutaneous diseases. Read More

View Article

Download full-text PDF

Source
January 2016
6 Reads

Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.

Skin Therapy Lett 2016 Jan;21(1):1-7

Spalding Drive Plastic Surgery and Cosmetic Dermatology, Beverly Hills, CA, USA.

Dyschromia is a leading cause for cosmetic consultation, especially in those with diverse skin types (mixture of ethnicities) and with the rise of non-core and untrained physicians performing cosmetic procedures. Melasma and post-inflammatory hyperpigmentation (PIH) account for the majority of cases and are characterized by pigmented macules and patches distributed symmetrically in sun-exposed areas of the forehead, cheeks, and chin in melasma, and irregularly in areas of inflammation or an inciting traumatic event with PIH. Treatment is challenging and focused on a variety of mechanisms to stop, hinder, and/or prevent steps in the pigment production (melanocytic hyperactivity) process, breaking down deposited pigment for internal removal or external release, exfoliating cells to enhance turnover, and decreasing inflammation. Read More

View Article

Download full-text PDF

Source
January 2016
88 Reads

Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.

Skin Therapy Lett 2015 Nov;20(6):6-9

Mediprobe Research Inc., London, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.

Onychomycosis is a stubborn fungal infection of the nails that can be difficult to effectively manage. One of the challenges with topical therapies is penetrating the nail plate to reach the site of infection. As the first antifungal in a boron-containing class of drugs with a novel mechanism of action, tavaborole is able to penetrate the nail plate more effectively than ciclopirox and amorolfine lacquers. Read More

View Article

Download full-text PDF

Source
November 2015
8 Reads

Sugar Sag: Glycation and the Role of Diet in Aging Skin.

Authors:
H P Nguyen R Katta

Skin Therapy Lett 2015 Nov;20(6):1-5

Department of Dermatology, Baylor College of Medicine, Houston, TX, USA.

First described in the context of diabetes, advanced glycation end products (AGEs) are formed through a type of non-enzymatic reaction called glycation. Increased accumulation of AGEs in human tissue has now been associated with end stage renal disease, chronic obstructive pulmonary disease, and, recently, skin aging. Characteristic findings of aging skin, including decreased resistance to mechanical stress, impaired wound healing, and distorted dermal vasculature, can be in part attributable to glycation. Read More

View Article

Download full-text PDF

Source
November 2015
58 Reads

DSM-5 Update in Psychodermatology.

Authors:
D A Nowak S M Wong

Skin Therapy Lett 2016 May;21(3):4-7

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.

Up to a third of dermatology outpatients have a significant psychiatric issue complicating their skin complaint. Although the ideal would frequently involve psychiatric assessment, those with comorbid mental illness often refuse psychiatric referral. As a result, it is imperative that dermatologists be mindful of psychiatric comorbidity in their patients and comfortable with the fundamentals of psychodermatologic diagnosis and therapy. Read More

View Article

Download full-text PDF

Source
May 2016
9 Reads

Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses.

Skin Therapy Lett 2016 May;21(3):1-3

Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada; Pacific Dermaesthetics, Vancouver, BC, Canada.

Actinic keratosis (AK), a common cutaneous lesion with the potential to transform into squamous cell carcinoma, has traditionally been treated with ablative and/or surgical procedures. Recently, a topical formulation combining 0.5% 5-fluorouracil with 10% salicylic acid (5-FU-SA) was introduced in Europe under the trade name Actikerall™ for the treatment of grade I/II AKs. Read More

View Article

Download full-text PDF

Source
May 2016
40 Reads

Nivolumab for Metastatic Melanoma.

Authors:
A K Gupta D Daigle

Skin Therapy Lett 2016 Mar;21(2):6-9

Mediprobe Research Inc., London, ON, Canada.

Melanoma is an aggressive skin cancer with a generally poor prognosis at Stage III-IV disease. Traditionally, metastatic melanoma was treated by surgical resection, when possible, and with systemic chemotherapy. New developments in molecular biology have led to the identification of immune checkpoints which are exploited by malignant cells, allowing them to go undetected by the immune system. Read More

View Article

Download full-text PDF

Source
March 2016
8 Reads

Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.

Skin Therapy Lett 2016 Mar;21(2):1-5

K. Papp Clinical Research, Waterloo, ON, Canada; Probity Medical Research, Waterloo, ON Canada.

Atopic dermatitis results when aberrant barrier function and immune activation occur within the skin. Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Of these, dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown the greatest promise. Read More

View Article

Download full-text PDF

Source
http://www.skintherapyletter.com/download/stl_21_2.pdf
Web Search
March 2016
26 Reads

New antibiotics in the management of acute bacterial skin and skin structure infections.

Skin Therapy Lett 2015 Sep-Oct;20(5):7-9

Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA.

Acute bacterial skin and skin-structure infections (ABSSSIs), often caused by aerobic gram-positive cocci, are most often mild-tomoderate infections that can easily be treated in an outpatient setting. With the rates of these infections substantially increasing in the past decade, owing in part to the emergence of community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA), alternative options for the treatment of ABSSSIs are necessary. This editorial reviews the mechanism of action, efficacy, bacterial coverage, and potential side effect profiles for dalbavancin and oritavancin, both semisynthetic lipoglycopeptide antibiotics, and tedizolid, an oxazolidinone. Read More

View Article

Download full-text PDF

Source
April 2016
3 Reads

Apremilast in the treatment of psoriasis and psoriatic arthritis.

Authors:
M Gooderham K Papp

Skin Therapy Lett 2015 Sep-Oct;20(5):1-6

K. Papp Clinical Research, Waterloo, ON, Canada; Probity Medical Research, Waterloo, ON, Canada.

Phosphodiesterase 4 (PDE4) is a key enzyme in the regulation of immune responses of inflammatory diseases through degradation of the second messenger, cyclic adenosine 3',5'-monophosphate (cAMP). Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines by increasing intracellular levels of cAMP and promoting the production of anti-inflammatory cytokines. The efficacy and safety of apremilast in the treatment of psoriasis and psoriatic arthritis has been demonstrated in phase 2 and 3 studies and will be reviewed here. Read More

View Article

Download full-text PDF

Source
April 2016
17 Reads

Ivermectin 1% cream for rosacea.

Skin Therapy Lett 2015 Jul-Aug;20(4):9-11

Henry Ford Medical Center, Department of Dermatology, Detroit, MI, USA.

The etiology of papulopustular rosacea (PPR) is not well understood yet appears to involve both the innate and adaptive immune response in addition to possible infestation with Demodex mites. Current treatments for PPR consist mainly of antibiotics. Ivermectin cream 1%, a new topical treatment for PPR, possesses both anti-inflammatory and anti-parasitic properties. Read More

View Article

Download full-text PDF

Source
April 2016
6 Reads

Hidradenitis suppurativa: a review with a focus on treatment data.

Skin Therapy Lett 2015 Jul-Aug;20(4):1-8

Department of Dermatology, University of Cincinnati, OH, USA.

Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life and usually affects the axillary, perineum and inframammary regions resulting in tender subcutaneous nodules, abscesses, fibrosis and sinus tract formation. New updates on HS underscores the role of various genes as well as the innate and adaptive immune response in its pathogenesis. Although every patient requires an individualized approach to treatment, topical therapy and antibiotics are mainly used for mild to moderate disease, whereas various systemic immune modulators and/or surgical approaches play a pivotal role in moderate to severe disease. Read More

View Article

Download full-text PDF

Source
April 2016
4 Reads

Current management of scalp psoriasis.

Authors:
L Guenther

Skin Therapy Lett 2015 May-Jun;20(3):5-7

Division of Dermatology, University of Western Ontario, London, ON, Canada; The Guenther Dermatology Research Centre (GDRC), London, ON, Canada.

The scalp is involved in up to 80% of individuals with psoriasis. Eighty percent of those with scalp psoriasis experience a negative impact on quality of life. Topical treatment with corticosteroids with or without vitamin D3 analogues is the mainstay of treatment. Read More

View Article

Download full-text PDF

Source
November 2016
8 Reads

Regulating off-label promotion of medications: has the pendulum swung too far?

Skin Therapy Lett 2015 May-Jun;20(3):1-4

Center for Dermatology Research, Departments of Dermatology, Pathology and Public Health Sciences; Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Prescribing medications off-label is commonplace in dermatology. Recent policy changes on the regulatory abilities of the US FDA and legal precedents regarding this topic have led to intense debate on free speech about off-label drug use by physicians and drug manufacturers. Here, we summarize and discuss the risks and benefits of off-label promotion and how this relates to quality patient care in dermatology. Read More

View Article

Download full-text PDF

Source
November 2016
9 Reads

Male aesthetics.

Authors:
Terrence Keaney

Skin Therapy Lett 2015 Mar-Apr;20(2):5-7

Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA.

Men are a fast growing segment of the aesthetic industry. A review was performed for publications on gender differences in facial anatomy, behavior, and the use of minimally invasive aesthetic procedures in men. There are substantial facial anatomical differences between genders with men having a larger but unique cranial shape, increased skeletal muscle mass, unique subcutaneous fat distribution, and more severe facial rhytides. Read More

View Article

Download full-text PDF

Source
June 2016
5 Reads

Interleukin-23 in the pathogenesis and treatment of psoriasis.

Skin Therapy Lett 2015 Mar-Apr;20(2):1-4

Center for Clinical Studies, Houston, TX, USA.

In the past three decades, major advances have been made in understanding the pathogenesis of psoriasis. The currently accepted theory is that T-cell mediated immune dysregulation triggers keratinocyte hyperproliferation in psoriasis. Recent research indicates that the Th17/interleukin (IL)-23 pathway plays a prominent role in the amplification phase of psoriasis. Read More

View Article

Download full-text PDF

Source
June 2016
6 Reads